Literature DB >> 9223490

Hepatitis C virus envelope proteins bind lactoferrin.

M Yi1, S Kaneko, D Y Yu, S Murakami.   

Abstract

Hepatitis C virus (HCV) has two envelope proteins, E1 and E2, which form a heterooligomer. During dissection of interacting regions of HCV E1 and E2, we found the presence of an interfering compound or compounds in skim milk. Here we report that human as well as bovine lactoferrin, a multifunctional immunomodulator, binds two HCV envelope proteins. As determined by far-Western blotting, the bacterially expressed E1 and E2 could bind lactoferrin in human milk directly separated or immunopurified and separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The bindings of lactoferrin and HCV envelope proteins in vitro were confirmed by another method, the pull-down assay, with immunoprecipitated lactoferrin-bound protein A resin. By the same assay, mammal-expressed recombinant E1 and E2 were also demonstrated to bind human lactoferrin efficiently in vitro. Direct interaction between E2 and lactoferrin was proved in vivo, since anti-human lactoferrin antibody efficiently coimmunoprecipitated with secreted and intracellular forms of the E2 protein, but not glutathione S-transferase (GST), from lysates of HepG2 cells transiently cotransfected with the expression plasmids of human lactoferrin and gE2t-GST (the N-terminal two-thirds of E2 fused to GST) or GST. The N-terminal loop of lactoferrin, the region important for the antibacterial activity, has only a little role in the binding ability to HCV E2 but affected the secretion or stability of lactoferrin. Taken together, these results indicate the specific interaction between lactoferrin and HCV envelope proteins in vivo and in vitro.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9223490      PMCID: PMC191856     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  29 in total

1.  The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients.

Authors:  S Okada; Y Akahane; H Suzuki; H Okamoto; S Mishiro
Journal:  Hepatology       Date:  1992-09       Impact factor: 17.425

2.  Delineation of regions important for heteromeric association of hepatitis C virus E1 and E2.

Authors:  M Yi; Y Nakamoto; S Kaneko; T Yamashita; S Murakami
Journal:  Virology       Date:  1997-04-28       Impact factor: 3.616

3.  Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp70) of hepatitis C virus.

Authors:  N Kato; H Sekiya; Y Ootsuyama; T Nakazawa; M Hijikata; S Ohkoshi; K Shimotohno
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

4.  Human hepatitis virus X gene encodes a regulatory domain that represses transactivation of X protein.

Authors:  S Murakami; J H Cheong; S Kaneko
Journal:  J Biol Chem       Date:  1994-05-27       Impact factor: 5.157

5.  Mother-to-infant transmission of hepatitis C virus.

Authors:  R Wejstål; A Widell; A S Månsson; S Hermodsson; G Norkrans
Journal:  Ann Intern Med       Date:  1992-12-01       Impact factor: 25.391

6.  Analysis of hepatitis C virus capsid, E1, and E2/NS1 proteins expressed in insect cells.

Authors:  R E Lanford; L Notvall; D Chavez; R White; G Frenzel; C Simonsen; J Kim
Journal:  Virology       Date:  1993-11       Impact factor: 3.616

7.  Possible role of high-titer maternal viremia in perinatal transmission of hepatitis C virus.

Authors:  H H Lin; J H Kao; H Y Hsu; Y H Ni; S H Yeh; L H Hwang; M H Chang; S C Hwang; P J Chen; D S Chen
Journal:  J Infect Dis       Date:  1994-03       Impact factor: 5.226

8.  Characterization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia viruses.

Authors:  R Ralston; K Thudium; K Berger; C Kuo; B Gervase; J Hall; M Selby; G Kuo; M Houghton; Q L Choo
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

9.  Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections.

Authors:  A J Weiner; H M Geysen; C Christopherson; J E Hall; T J Mason; G Saracco; F Bonino; K Crawford; C D Marion; K A Crawford
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-15       Impact factor: 11.205

10.  Expression and identification of hepatitis C virus polyprotein cleavage products.

Authors:  A Grakoui; C Wychowski; C Lin; S M Feinstone; C M Rice
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

View more
  31 in total

1.  Bovine lactoferrin inhibits adenovirus infection by interacting with viral structural polypeptides.

Authors:  Agostina Pietrantoni; Assunta Maria Di Biase; Antonella Tinari; Magda Marchetti; Piera Valenti; Lucilla Seganti; Fabiana Superti
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

2.  Bovine lactoferrin-derived peptides as novel broad-spectrum inhibitors of influenza virus.

Authors:  Maria Grazia Ammendolia; Mariangela Agamennone; Agostina Pietrantoni; Fabio Lannutti; Rosa Anna Siciliano; Beatrice De Giulio; Carla Amici; Fabiana Superti
Journal:  Pathog Glob Health       Date:  2012-03       Impact factor: 2.894

3.  Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus.

Authors:  Andréa Allaire; Frédéric Picard-Jean; Martin Bisaillon
Journal:  J Vis Exp       Date:  2015-10-01       Impact factor: 1.355

4.  The missing pieces of the HCV entry puzzle.

Authors:  Sarah C Ogden; Hengli Tang
Journal:  Future Virol       Date:  2015       Impact factor: 1.831

5.  Decreased tear lactoferrin concentration in patients with chronic hepatitis C.

Authors:  T Abe; A Nakajima; M Matsunaga; S Sakuragi; M Komatsu
Journal:  Br J Ophthalmol       Date:  1999-06       Impact factor: 4.638

6.  Inhibition of HBV infection by bovine lactoferrin and iron-, zinc-saturated lactoferrin.

Authors:  Songtao Li; Haibo Zhou; Guirong Huang; Ning Liu
Journal:  Med Microbiol Immunol       Date:  2008-09-23       Impact factor: 3.402

7.  Effect of infusing lactoferrin hydrolysate into bovine mammary glands with subclinical mastitis.

Authors:  K Kawai; H Nagahata; N Y Lee; A Anri; K Shimazaki
Journal:  Vet Res Commun       Date:  2003-10       Impact factor: 2.459

Review 8.  The Immunological Role of the Placenta in SARS-CoV-2 Infection-Viral Transmission, Immune Regulation, and Lactoferrin Activity.

Authors:  Iwona Bukowska-Ośko; Marta Popiel; Paweł Kowalczyk
Journal:  Int J Mol Sci       Date:  2021-05-28       Impact factor: 5.923

9.  Effectiveness of human, camel, bovine and sheep lactoferrin on the hepatitis C virus cellular infectivity: comparison study.

Authors:  Esmail M El-Fakharany; Lourdes Sánchez; Hussein A Al-Mehdar; Elrashdy M Redwan
Journal:  Virol J       Date:  2013-06-19       Impact factor: 4.099

Review 10.  Current scenario of peptide-based drugs: the key roles of cationic antitumor and antiviral peptides.

Authors:  Kelly C L Mulder; Loiane A Lima; Vivian J Miranda; Simoni C Dias; Octávio L Franco
Journal:  Front Microbiol       Date:  2013-10-31       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.